• MALDI Biotyper® (MBT): Launch of proprietary MBT Easy T® Kit for consistent sample transfer to MALDI target plates
  • MALDI Biotyper®: Expansion of reference libraries to more than 5,300 species, spanning bacteria, yeasts, filamentous fungi, and mycobacteria
  • MALDI Biotyper®: Early KOL access to a novel cloud‑based identification solution, enabling identification against several specialist, expert‑curated libraries
  • MALDI Biotyper®: Ongoing broad, multi‑year clinical and translational study programs advancing automation, potential future claims, and next‑generation analytics, including:
    • IVDR-compliant clinical validation studies evaluating automated sample preparation workflows, covering both colony‑based cultures (MBT PrepMatic™) and positive blood cultures (MBT SepsiMatic®)
    • U.S. clinical studies intended to support upcoming identification claims for mycobacteria and filamentous fungi, with FDA submission targeted for 2026
    • Ongoing clinical evaluation of MBT FAST, a rapid phenotypic antimicrobial susceptibility testing approach, aiming to enable IVDR-compliant same‑day results from positive blood cultures and agar colonies for Enterobacteriaceae
    • Exploratory, data‑driven research studies presented at ESCMID, including AI‑based antibiotic resistance prediction for Staphylococcus aureus, derived from large MALDI Biotyper spectral datasets
  • IR Biotyper®: Enhanced outbreak detection with IR Tracker for surveillance of hospital‑acquired infections (HAIs) and new classifiers for Salmonella Typhi, STEC, and Shigella sp. detection
  • MBioSEQ™ Ridom Typer: New software version, including TB‑Profiler antimicrobial resistance (AMR) determination, and GAMBIT bacterial species identification supporting MALDI / IR Biotyper®-triggered WGS reflex testing workflows, with result application performed under laboratory responsibility
  • Introduction of Molzym as a part of Bruker Microbiology and Infection Diagnostics